NEONATAL RESPIRATORY TRIALS IN SICK & PRETERM NEWBORN INFANTS
Professor Brett J. Manley, Consultant Neonatologist
Mercy Hospital For Women, Melbourne & Professor of Neonatal Medicine, Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | August 2025
Professor Brett J. Manley is a Consultant Neonatologist at the Mercy Hospital for Women in Melbourne, Australia, and a Professor of Neonatology in the Department of Obstetrics, Gynaecology and Newborn Health at The University of Melbourne. His research is supported by a fellowship from the National Health and Medical Research Council (NHMRC), Australia.
He divides his work time between being a clinician in the neonatal intensive care unit (NICU), and a clinical researcher. He is passionate about caring for sick and preterm newborn infants and contributing to the evidence base for their care, to improve their shorter- and longer-term outcomes.
Prof Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
Source: Supplied
https://orcid.org/0000-0003-0212-7956
-
Identification, characterisation and role of leader cells in ovarian cancer progression
Dr. Maree Bilandzic is a molecular cancer biologist dedicated to advancing the understanding and treatment of ovarian cancer (OC). Her research addresses critical gaps in OC treatment by investigating the mechanisms behind metastasis, chemotherapy resistance, and tumour recurrence. By utilising innovative methodologies and disease-representative models, Dr. Bilandzic has pioneered the identification and characterisation of leader cells (LCs)—a unique, stem-like subpopulation within tumours that plays a crucial role in OC progression.
-
Non-invasive tools for CVD screening and monitoring
Dr Hadi Afsharan is a Research Fellow Cardiovascular Science & Diabetes at the Harry Perkins Institute of Medical Research; is a translational research and innovation fellow in medical technologies at The University of Western Australia, holding dual titles as Translational Fellow and Innovation Fellow within UWA’s Medical School and the FHRI (Future Health Research and Innovation) program.
-
Clinical guidelines for diagnostics and early intervention in Primary Aldosteronism
Primary Aldosteronism (PA), or Conn Syndrome, is the most commonly under-diagnosed cause of high blood pressure affecting millions of people. Associate Professor Jun Yang’s goal is to facilitate the diagnosis of every case of PA and make treatment widely available to all communities including the disadvantaged.
